Estimating The Economic and Clinical Benefits of Mirabegron Versus Antimuscarinics for The Treatment of Overactive Bladder (OAB) in The United Kingdom (UK)

Autor:	Jameel Nazir, C McCrea, Adrian Wagg, Francis Fatoye, Zalmai Hakimi, M Berling
Rok vydání:	2016
Předmět:	medicine.medical_specialty Overactive bladder business.industry Health Policy Public Health Environmental and Occupational Health medicine Urology medicine.disease Mirabegron business medicine.drug
Zdroj:	Value in Health. 19:A518
ISSN:	1098-3015
DOI:	10.1016/j.jval.2016.09.996
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f28938c85d3e17454096eef1b4af7dc9 https://doi.org/10.1016/j.jval.2016.09.996 Zobrazit plný text záznamu Full Text from ScienceDirect